June 6, 2000Annals of Internal Medicine
Ardeparin Sodium for Extended Out-of-Hospital Prophylaxis against Venous Thromboembolism after Total Hip or Knee Replacement
Why the study?
Does extended out-of-hospital ardeparin prophylaxis reduce symptomatic venous thromboembolism or death in adults after total hip or knee replacement?
Population
1195 adults who had elective total hip or knee replacement and completed 4 to 10 days of postoperative…
Comparison
Daily subcutaneous ardeparin from time of… vs Placebo from time of hospital discharge to 6…
Design
RCT, Randomized, double-blind
Follow-up
12 weeks after surgery
Authors
Discussion
Loading...
Member takes
Implication
Extended ardeparin prophylaxis does not reduce post-discharge VTE or death after hip/knee replacement; challenges routine prolonged use.
Structured PICO
Does extended out-of-hospital ardeparin prophylaxis reduce symptomatic venous thromboembolism or death in adults after total hip or knee replacement?
P
Population
1195 adults who had elective total hip or knee replacement and completed 4 to 10 days of postoperative ardeparin prophylaxis
I
Intervention
Daily subcutaneous ardeparin (100 anti-Xa IU/kg of body weight) from time of hospital discharge to 6 weeks after surgery
C
Comparator
Placebo from time of hospital discharge to 6 weeks after surgery
O
Outcome
Symptomatic, objectively documented venous thromboembolism or death from time of hospital discharge to 12 weeks after surgerycomposite
Extended out-of-hospital prophylaxis with ardeparin for 6 weeks after total hip or knee replacement does not significantly reduce the incidence of symptomatic venous thromboembolism or death.
Cite This Study
Heit et al. (2000) studied this question.